Re-examination of participants from the Swedish CArdioPulmonary bioImage Study

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Swedish CArdioPulmonary bioImage Study 2 (SCAPIS 2) aims to re-examine approximately 15,000 individuals who participated in the original SCAPIS study, conducted between 2013 and 2018. This observational study will assess the progression of cardiovascular and lung diseases by utilizing various diagnostic methods, including CCTA, ECG, and spirometry, to gather data on risk factors and disease mechanisms. The study focuses on understanding the natural progression of atherosclerosis and lung function over an 8-10 year period, providing valuable insights into the long-term health of the participants. By comparing outcomes between those invited to SCAPIS 2 and those not invited, the study seeks to enhance prediction and prevention strategies for these diseases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- Participated in SCAPIS 1.

Exclusion Criteria:

* Individuals who have withdrawn their informed consent during or after SCAPIS 1.

Where it's running

• Gothenburg University
  Gothenburg, Sweden Recruiting
• Linköping University
  Linköping, Sweden Recruiting
• Lund University
  Lund, Sweden Recruiting
• Karolinska Institutet
  Stockholm, Sweden Recruiting
• Umeå Universitet
  Umeå, Sweden Recruiting
• Uppsala University
  Uppsala, Sweden Recruiting

Study contacts

• Principal investigator: Carl Johan Östgren, PhD — Linkoeping University
• Study coordinator: Tomas Jernberg, PhD
• Email: tomas.jernberg@ki.se
• Phone: +46-70-1671474

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mosliciguat added to inhaled treprostinil for pulmonary hypertension from ILD

  This trial tests whether adding inhaled mosliciguat to your inhaled treprostinil is safe and tolerable for people with pulmonary hypertension caused by interstitial lung disease.

  Recruiting at 13 sites Phase 2 Pulmovant, Inc. · Santa Barbara, California and 12 other locations · NCT07333183

• Comparing clinical surveillance to anticoagulation for low-risk patients with isolated pulmonary embolism

  This study is testing whether low-risk patients with isolated pulmonary embolism can safely be monitored without blood thinners instead of taking them.

  Recruiting at 29 sites Phase 4 Insel Gruppe AG, University Hospital Bern · Woluwe-Saint-Lambert, Brussels Capital and 39 other locations · NCT04263038

• Examining health determinants and their impact on chronic diseases

  This study looks at how personal choices and community factors affect heart health and other long-term illnesses to see what really impacts people's health.

  Recruiting at 34 sites Population Health Research Institute · Rosario, Santa Fe Province and 33 other locations · NCT03225586

• Abnormal menstrual bleeding in women on antithrombotic drugs after heart surgery

  This study looks at whether women on blood thinners after heart surgery have abnormal menstrual bleeding and what factors might put some at higher risk.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07870941

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.